Paul Campbell

Dr. Paul Campbell

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2022 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
KRKristopher S. Raghavan
Kristopher S. Raghavan
RFRalph Francescone
Ralph Francescone
JFJanusz Franco-Barraza
Janusz Franco-Barraza
JGJaye C. Gardiner
Jaye C. Gardiner
DVDébora B. Vendramini-Costa
Débora B. Vendramini-Costa
ECEdna Cukierman
Edna Cukierman
It is projected that in 5 years, pancreatic cancer will become the second deadliest cancer in the United States. A unique aspect of pancreatic ductal adenocarcinoma (PDAC) is its stroma; rich in cancer-associated fibroblasts (CAFs) and a dense CAF-generated extracellular matrix (ECM). These pathogenic stroma CAF/ECM units cause the collapse of local blood vessels rendering the tumor microenvironment nutrient-poor. PDAC cells are able to survive this state of nutrient stress via support from CAF-secreted material, which includes small extracellular vesicles (sEV). The tumor-supportive CAFs possess a distinct phenotypic profile, compared with normal-like fibroblasts, expressing NetrinG1 (NetG1) at the plasma membrane, and active Integrin α5β1 localized to the multivesicular bodies; traits indicative of poor patient survival. We herein report that NetG1+ CAFs secrete sEVs that stimulate Akt-mediated survival in nutrient-deprived PDAC cells, protecting them from undergoing apoptosis. Furthermore, we show that NetG1 expression in CAFs is required for the prosurvival properties of sEVs. In addition, we report that the above-mentioned CAF markers are secreted in distinct subpopulations of EVs; with NetG1 being enriched in exomeres, and Integrin α5β1 being enriched in exosomes. Finally, we found that NetG1 and Integrin α5β1 were detected in sEVs collected from plasma of patients with PDAC, while their levels were significantly lower in plasma-derived sEVs of sex/age-matched healthy donors. The discovery of these tumor-supporting CAF-EVs elucidates novel avenues in tumor–stroma interactions and pathogenic stroma detection.Significance: Results from this study identified two unique types of tumor-supporting CAF EVs, with evidence of these being detected in patients. Thus, this study facilitates a novel avenue to further dissect the subtleties of the tumor–stroma interactions responsible for PDAC homeostasis and progression, as well as the possibility of establishing future means to detect and monitor dynamic stroma staging.

2 November 2010 in Journal of Molecular Signaling
Verified
Journal Article
Open access
PDF file
PCPaul Campbell
Paul Campbell
NBNadia Boufaied
Nadia Boufaied
JFJames J Fiordalisi
James J Fiordalisi
ACAdrienne D Cox
Adrienne D Cox
PFPierre Falardeau
Pierre Falardeau
HGHenriette Gourdeau
Henriette Gourdeau
TLN-4601 is a structurally novel farnesylated dibenzodiazepinone discovered using Thallion's proprietary DECIPHER® technology, a genomics and bioinformatics platform that predicts the chemical structures of secondary metabolites based on gene sequences obtained by scanning bacterial genomes. Our recent studies suggest that TLN-4601 inhibits the Ras-ERK MAPK pathway post Ras prenylation and prior to MEK activation. The Ras-ERK MAPK signaling pathway is a well-validated oncogenic cascade based on its central role in regulating the growth and survival of cells from a broad spectrum of human tumors. Furthermore, RAS isoforms are the most frequently mutated oncogenes, occurring in approximately 30% of all human cancers, and KRAS is the most commonly mutated RAS gene, with a greater than 90% incidence of mutation in pancreatic cancer.

1 September 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
SOSelahattin C. Ozcan
Selahattin C. Ozcan
AMAydan Mutlu
Aydan Mutlu
TATugba H. Altunok
Tugba H. Altunok
YGYunus Gurpinar
Yunus Gurpinar
ASAybike Sarıoğlu-Bozkurt
Aybike Sarıoğlu-Bozkurt
AYAbdullah YALÇIN
Abdullah YALÇIN

10 June 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
BSBailee Sliker
Bailee Sliker
PCPaul Campbell
Paul Campbell
Tumors are composed of not only epithelial cells but also many other cell types that contribute to the tumor microenvironment (TME). Within this space, cancer-associated fibroblasts (CAFs) are a prominent cell type, and these cells are connected to an increase in tumor progression as well as alteration of the immune landscape present in and around the tumor. This is accomplished in part by their ability to alter the presence of both innate and adaptive immune cells as well as the release of various chemokines and cytokines, together leading to a more immunosuppressive TME. Furthermore, new research implicates CAFs as players in immunotherapy response in many different tumor types, typically by blunting their efficacy. Fibroblast activation protein (FAP) and transforming growth factor β (TGF-β), two major CAF proteins, are associated with the outcome of different immunotherapies and, additionally, have become new targets themselves for immune-based strategies directed at CAFs. This review will focus on CAFs and how they alter the immune landscape within tumors, how this affects response to current immunotherapy treatments, and how immune-based treatments are currently being harnessed to target the CAF population itself.

1 December 2018 in Biochemical Pharmacology
Verified
Journal Article
Closed access
MSMatthew C. Stout
Matthew C. Stout
PCPaul Campbell
Paul Campbell